Press Releases

News Brief

Samsung Biologics hosts ‘Biopharma Safety and Health Forum’

Samsung Biologics hosts ‘Biopharma Safety and Health Forum’
 

Samsung Biologics hosted the first ‘Biopharma Safety and Health Forum,’ inviting the public and private sector to discuss measures to strengthen workplace safety and health.

 

The forum, the first of its kind, brought together officials from Korea’s labor ministry and occupational safety and health agency, as well as 11 biopharma companies, to discuss the government’s health and safety policies. Samsung Biologics shared its expertise in process safety management and successful case studies regarding the establishment of health-related infrastructure for employees.

 

“We held in-depth discussions on ways to bolster safety and health management at local biopharma companies,” said Kun Lo, Executive Vice President of Engineering, Procurement, Construction, and Validation (EPCV) at Samsung Biologics. “Based on the insights shared, we look forward to the implementation of activities and policies suited for each company.”

 

Samsung Biologics will host two more sessions in the latter of this year, while the labor ministry plans to provide incentives to biopharma companies that take part.

Samsung Biologics hosts ‘Biopharma Safety and Health Forum’
 

Samsung Biologics hosted the first ‘Biopharma Safety and Health Forum,’ inviting the public and private sector to discuss measures to strengthen workplace safety and health.

 

The forum, the first of its kind, brought together officials from Korea’s labor ministry and occupational safety and health agency, as well as 11 biopharma companies, to discuss the government’s health and safety policies. Samsung Biologics shared its expertise in process safety management and successful case studies regarding the establishment of health-related infrastructure for employees.

 

“We held in-depth discussions on ways to bolster safety and health management at local biopharma companies,” said Kun Lo, Executive Vice President of Engineering, Procurement, Construction, and Validation (EPCV) at Samsung Biologics. “Based on the insights shared, we look forward to the implementation of activities and policies suited for each company.”

 

Samsung Biologics will host two more sessions in the latter of this year, while the labor ministry plans to provide incentives to biopharma companies that take part.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION